Emergent Biosolutions (NYSE:EBS) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Emergent Biosolutions (NYSE:EBS) from a buy rating to a hold rating in a report published on Sunday morning.

EBS has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. Weiss Ratings downgraded shares of Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, March 2nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $12.00.

Emergent Biosolutions Trading Up 0.4%

Emergent Biosolutions stock opened at $8.38 on Friday. The stock has a market cap of $440.28 million, a P/E ratio of 9.98 and a beta of 2.41. Emergent Biosolutions has a fifty-two week low of $4.02 and a fifty-two week high of $14.06. The firm’s fifty day moving average price is $11.14 and its 200-day moving average price is $10.40. The company has a debt-to-equity ratio of 1.09, a quick ratio of 2.41 and a current ratio of 5.01.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.54). Emergent Biosolutions had a net margin of 7.08% and a return on equity of 15.86%. The business had revenue of $148.70 million for the quarter, compared to the consensus estimate of $217.50 million. Equities research analysts forecast that Emergent Biosolutions will post -0.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Emergent Biosolutions

Several hedge funds have recently added to or reduced their stakes in EBS. Millennium Management LLC increased its position in shares of Emergent Biosolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after purchasing an additional 1,020,582 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Emergent Biosolutions by 12.5% in the first quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock worth $5,301,000 after buying an additional 121,583 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Emergent Biosolutions by 5.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 986,673 shares of the biopharmaceutical company’s stock worth $6,295,000 after buying an additional 55,046 shares in the last quarter. Acadian Asset Management LLC grew its position in Emergent Biosolutions by 17.0% during the second quarter. Acadian Asset Management LLC now owns 974,590 shares of the biopharmaceutical company’s stock valued at $6,216,000 after acquiring an additional 141,274 shares during the last quarter. Finally, Prescott Group Capital Management L.L.C. grew its position in Emergent Biosolutions by 23.1% during the second quarter. Prescott Group Capital Management L.L.C. now owns 772,771 shares of the biopharmaceutical company’s stock valued at $4,930,000 after acquiring an additional 145,100 shares during the last quarter. Institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.